These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3126293)

  • 1. Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine.
    Criswell H; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1988 Feb; 244(2):493-500. PubMed ID: 3126293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
    Criswell HE; Johnson KB; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
    Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
    Breese GR; Baumeister A; Napier TC; Frye GD; Mueller RA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):287-95. PubMed ID: 3932640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP
    Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine deficiency in self-injurious behavior.
    Breese GR; Criswell HE; Duncan GE; Mueller RA
    Psychopharmacol Bull; 1989; 25(3):353-7. PubMed ID: 2697009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment.
    Brus R; Kostrzewa RM; Perry KW; Fuller RW
    J Pharmacol Exp Ther; 1994 Jan; 268(1):231-7. PubMed ID: 8301563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal destruction of dopaminergic neurons.
    Breese GR; Criswell HE; Johnson KB; O'Callaghan JP; Duncan GE; Jensen KF; Simson PE; Mueller RA
    Neurotoxicology; 1994; 15(1):149-59. PubMed ID: 8090354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors.
    Yokoyama C; Okamura H
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1016-30. PubMed ID: 9023319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat.
    Breese GR; Criswell HE; Duncan GE; Mueller RA
    Brain Res Bull; 1990 Sep; 25(3):477-84. PubMed ID: 2127238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.